september 29, 2018, tai heng received official letter from the us fda，which is in reference to our dmf（#024838）for imatinib mesylate. the letter indicated that fda had completed the full scientific review of this dmf and had found the dmf to be adequate to support an anda submission. tai heng commites that if there are any future changes to the dmf, we will promptly report to the fda and inform our customers per 21 cfr 314.420(c).
订阅电子期刊
返回
上海泰亨实业集团有限公司
微信公众号